ESR1 and cancer: Additionally, genes downregulated by CAFs in cancer cells correlated with lower ET sensitivity, and the transforming growth factor-β (TGF-β) and Janus kinase signaling pathways were identified as potential targets to counteract CAF-driven changes through ER-α modulation [18].